Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.
Brun S, Bestion E, Raymond E, Bassissi F, Jilkova ZM, Mezouar S, Rachid M, Novello M, Tracz J, Hamaï A, Lalmanach G, Vanderlynden L, Legouffe R, Stauber J, Schubert T, Plach MG, Courcambeck J, Drouot C, Jacquemot G, Serdjebi C, Roth G, Baudoin JP, Ansaldi C, Decaens T, Halfon P. Brun S, et al. Among authors: raymond e. Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357. Epub 2021 Nov 5. Autophagy. 2022. PMID: 34740311 Free PMC article.
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E. Harding JJ, et al. Among authors: raymond e. Liver Cancer. 2022 Feb 15;11(3):268-277. doi: 10.1159/000522418. eCollection 2022 Jun. Liver Cancer. 2022. PMID: 35949290 Free PMC article.
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E. Hilgers W, et al. Among authors: raymond e. Invest New Drugs. 2006 Jul;24(4):311-9. doi: 10.1007/s10637-005-5055-6. Invest New Drugs. 2006. PMID: 16683074 Clinical Trial.
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J, Kahatt C, Bertheault-Cvitkovic F, Faivre S, Shibata S, Hilgers W, Goldwasser F, Lokiec F, Raymond E, Weems G, Shah A, MacDonald JR, Cvitkovic E. Alexandre J, et al. Among authors: raymond e. Invest New Drugs. 2007 Oct;25(5):453-62. doi: 10.1007/s10637-007-9071-6. Epub 2007 Jul 13. Invest New Drugs. 2007. PMID: 17628744 Clinical Trial.
599 results